CSL Biotherapies

Delivering vaccines is our mission;
protecting lives, our passion
Innovation and new product development for unmet medical needs continue to drive CSL’s growth.

CSL Limited

- Headquarters: Melbourne, Australia
- 8,500+ employees in 25 countries
- 90+ years experience in the development and manufacture of vaccines and plasma protein biotherapies
- 05/06 sales revenue: AU$2.8 billion
- Listed on the Australian Stock Exchange (ASX: CSL) since 1994
- www.csl.com.au
CSL’s Global Flu Vaccine Business

- Manufactured flu vaccine since 1968
- Flu vaccines sold in 16 countries worldwide
- Bulk antigen supplied for vaccine sold in 24 countries
- 2005/06 season, one in four flu vaccine recipients in the U.K. vaccinated with a CSL product

*Filtration process at CSL’s new flu vaccine center*
Vaccine Manufacturing Capability

- Modern egg processing facility completed in 2004
- Manufactures both Northern and Southern Hemisphere strains
- GMP compliance for Europe and Australia
- $60mm investment in capacity increase under way
CSL’s Flu Vaccine in the U.S.

• CSL Biotherapies will commercialize the flu vaccine in the U.S.
• Two presentations:
  • Pre-filled syringe (thimerosal-free)
  • Multi-dose vial
• US Clinical trial completed (1,400 patients)
• Planned for 2007/08 season
ISCOMATRIX® adjuvant

- Saponin-based
- Provides both antigen delivery and immunomodulatory properties
- Enhancement of the immune response on the cellular and T-Cell activity
- Antigen dose reduction properties
- Manufacture ZLB Behring’s Kankakee
- Multiple partners and applications
Delivering vaccines is our mission; protecting lives our passion